Literature DB >> 11549561

Observation and experiment with the efficacy of drugs: a warning example from a cohort of nonsteroidal anti-inflammatory and ulcer-healing drug users.

A D McMahon1.   

Abstract

Observational data are well suited for many types of medical research, especially when randomized controlled trials are inappropriate. However, some researchers have attempted to justify routine use of observational data in situations in which randomized controlled trials are normally conducted. Literature searches cannot be used to directly compare the results of the two types of research, because invalid observational studies normally are not publishable in the journal literature. The author created a study (1989-1994) to determine the efficacy of one exposure (ulcer-healing drugs) in preventing the serious upper gastrointestinal toxicity associated with another exposure (nonsteroidal anti-inflammatory drugs (NSAIDs)). A cohort of subjects from Tayside, Scotland, receiving both NSAIDs and ulcer-healing drugs appeared to experience a large rise in their risk of gastric bleeding and perforation (e.g., the rate ratio was 10.00 (95% confidence interval: 6.68, 14.97) when this cohort was compared with one receiving NSAIDs alone). This increased risk was due to confounding. Thus, use of a "restricted cohort design" was not able to eliminate uncontrollable bias. It is possible that if many different studies were carried out, then observational research would be found to be only occasionally useful for studying drug efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549561     DOI: 10.1093/aje/154.6.557

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  6 in total

Review 1.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

Review 2.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Eric Abadie; David Barnett; Franz König; Steven Pearson
Journal:  Nat Rev Drug Discov       Date:  2010-02-26       Impact factor: 84.694

3.  N'-[(E)-4-Meth-oxy-benzyl-idene]-2-(5-meth-oxy-2-methyl-1H-indol-3-yl)acetohydrazide.

Authors:  Mehmet Akkurt; Joel T Mague; Shaaban K Mohamed; Antar A Abelhamid; Mustafa R Albayati
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-10-19

4.  Estimation of treatment effects in observational stroke care data: comparison of statistical approaches.

Authors:  Marzyeh Amini; Nikki van Leeuwen; Frank Eijkenaar; Rob van de Graaf; Noor Samuels; Robert van Oostenbrugge; Ido R van den Wijngaard; Pieter Jan van Doormaal; Yvo B W E M Roos; Charles Majoie; Bob Roozenbeek; Diederik Dippel; James Burke; Hester F Lingsma
Journal:  BMC Med Res Methodol       Date:  2022-04-10       Impact factor: 4.615

5.  Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings.

Authors:  Richard L Tannen; Mark G Weiner; Dawei Xie
Journal:  BMJ       Date:  2009-01-27

6.  Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.

Authors:  Turki A Althunian; Anthonius de Boer; Rolf H H Groenwold; Katrien O Rengerink; Patrick C Souverein; Olaf H Klungel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-06-14       Impact factor: 2.890

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.